首页> 外文期刊>Journal of Cancer >Association between Pretreatment Serum High-density Lipoprotein Cholesterol and Treatment Outcomes in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy: Findings from a Randomised Trial
【24h】

Association between Pretreatment Serum High-density Lipoprotein Cholesterol and Treatment Outcomes in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy: Findings from a Randomised Trial

机译:放化疗治疗局部晚期鼻咽癌患者化疗前血清高密度脂蛋白胆固醇与治疗结果的关联:一项随机试验的结果

获取原文
       

摘要

Background : To investigate the relationship between the pretreatment serum lipid concentrations and the clinical outcomes in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) who were treated with a combination of chemotherapy and radiotherapy. Methods : From August 2002 to April 2005, 400 patients with stage III or stage IVa nasopharyngeal carcinoma were recruited for a randomised clinical trial of induction chemotherapy combined with radiotherapy or concurrent chemoradiotherapy. Pretreatment serum lipid concentrations were examined in 342 patients. Both univariate and multivariate analyses were conducted to investigate the association of serum lipid levels with different treatment outcomes. Results : The 5-year failure-free survival rate for the low- high-density lipoprotein cholesterol (HDL-C) and high-HDL-C groups was 52.1% and 65.5%, respectively ( p =0.017), and the 5-year overall survival rate was 64.7% and 72.5%, respectively ( p =0.094). The pretreatment serum level of HDL-C was a favourable prognostic factor of overall survival and failure-free survival in a Cox regression model with HR 0.65 (95% CI 0.43-0.97; p =0.036) and 0.60 (95% CI 0.41-0.88; p =0.008). No significant correlation was observed between the prognosis of patients with NPC and serum levels of total cholesterol (TC), triglyceride (TG), or low-density lipoprotein cholesterol (LDL-C). Conclusions : The pretreatment serum level of HDL-C was an independent prognostic factor for patients with locoregionally advanced nasopharyngeal carcinoma who were treated with chemoradiotherapy.
机译:背景:探讨局部局部晚期鼻咽癌(NPC)联合化疗和放疗的患者治疗前血脂浓度与临床结局之间的关系。方法:从2002年8月至2005年4月,招募400例III期或IVa期鼻咽癌患者,进行诱导化疗联合放疗或同步放化疗的随机临床试验。检查了342例患者的治疗前血清脂质浓度。进行单因素和多因素分析以研究血清脂质水平与不同治疗结果之间的关系。结果:低高密度脂蛋白胆固醇(HDL-C)组和高HDL-C组的5年无故障生存率分别为52.1%和65.5%(p = 0.017),而5年总生存率分别为64.7%和72.5%(p = 0.094)。在HR为0.65(95%CI 0.43-0.97; p = 0.036)和0.60(95%CI 0.41-0.88)的Cox回归模型中,HDL-C的预处理血清水平是总体生存和无失败生存的有利预后因素; p = 0.008)。 NPC患者的预后与血清总胆固醇(TC),甘油三酸酯(TG)或低密度脂蛋白胆固醇(LDL-C)的水平之间没有显着相关性。结论:HDL-C的预处理水平是局部放疗的鼻咽癌放化疗患者的独立预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号